Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ced/llae309 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Upadacitinib: the JAK inhibitor that achieved what other drugs could not.
Rev Esp Enferm Dig
January 2025
Gastroenterology, Hospital Universitario Infanta Elena, Spain.
We present an interesting case of severe ulcerative colitis flare, of challenging management because of a cytomegalovirus co-infection, in which upadacitinib achieved clinical and biochemical remission after poor responses to ganciclovir and tofacitinib.
View Article and Find Full Text PDFWeight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis.
JAAD Int
April 2025
Division of Dermatology, McMaster University, Hamilton, Canada.
Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster. Recent reports have linked JAKi usage to weight changes, particularly weight gain, which can significantly impact patients' quality of life.
View Article and Find Full Text PDFAn Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study.
Biomedicines
January 2025
Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou 515000, China.
Inflammatory bowel disease (IBD) requires effective treatment options. Upadacitinib, a Janus kinase 1 (JAK1) inhibitor, has shown effectiveness in trials for Crohn's disease (CD) and ulcerative colitis (UC). This study evaluates its real-world effectiveness and safety.
View Article and Find Full Text PDFEsophageal lichen planus treated with upadacitinib.
Rev Esp Enferm Dig
January 2025
General and Digestive Surgery. Esophagogastric Unit, Hospital Clínico Universitario Virgen de la Arrixaca.
Esophageal lichen planus (ELP) is a rare chronic inflammatory condition with delayed diagnosis that can present with dysphagia. It has been scarcely studied in the literature, and clinical management guidelines are lacking. Stenosis and neoplastic transformation are among its most feared complications.
View Article and Find Full Text PDFAntiphospholipid syndrome is an autoimmune disease characterised by thrombotic and/or obstetric manifestations with persistent antiphospholipid antibodies. Diagnosis involves confirming the persistence of antiphospholipid antibodies in symptomatic patients, using validated classification criteria as a guide. The likelihood of obtaining false-positive or false-negative test results in certain settings, and the lack of standardisation between laboratory methods, are important considerations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!